telisotuzumab adizutecan (ABBV-400)

News alerts, weekly reports and conference planners

Company:

AbbVie

Drug class:

Topoisomerase I inhibitor, c-MET-targeted antibody-drug conjugate

MET amplification	Solid Tumor	MET amplification	Solid Tumor	ABBV-400 Sensitive: C2 – Inclusion Criteria ABBV-400 Sensitive : C2	ABBV-400 Sensitive: C2 – Inclusion Criteria ABBV-400 Sensitive : C2
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	ABBV-400 Sensitive: C3 – Early Trials ABBV-400 Sensitive : C3	ABBV-400 Sensitive: C3 – Early Trials ABBV-400 Sensitive : C3
TMB-H	Colorectal Cancer	TMB-H	Colorectal Cancer	ABBV-400 Sensitive: C3 – Early Trials ABBV-400 Sensitive : C3	ABBV-400 Sensitive: C3 – Early Trials ABBV-400 Sensitive : C3

Associations
(3)